Phare Bio and Basilea Announce Landmark Partnership to Develop Next-Generation Broad-Spectrum Antibiotic Using AI
Phare Bio, a biotech social venture harnessing artificial intelligence to accelerate antibiotic discovery and development, and Basilea Pharmaceutica, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today a strategic partnership to jointly develop a novel broad-spectrum antibiotic to address critical unmet needs for patients battling life-threatening infections caused by high-priority gram-negative pathogens.
Phare Bio Wins Newsweek’s AI Impact Award for “Most Innovative Technology or Service”
Phare Bio, a biotech social venture harnessing generative AI to develop novel antibiotics, has been named the winner of the “Best Of – Most Innovative Technology or Service” category in Newsweek’s 2025 AI Impact Awards. The honor recognizes Phare Bio’s pioneering work using AI to combat the urgent global health crisis of antimicrobial resistance (AMR).
Phare Bio and MIT Named to Fast Company’s 2025 World Changing Ideas List
Fast Company has named Phare Bio, a biotech social venture, and MIT’s Collins Lab, to its 2025 World Changing Ideas list for their breakthrough use of generative AI to design entirely novel antibiotics – a paradigm-shifting approach in the global fight against antimicrobial resistance (AMR).
Phare Bio Selected to Participate in the Google.org Accelerator: Generative AI to Advance Open-Access Antibiotic Discovery Platform
Phare Bio, a biotech social venture using AI to combat the global antibiotic resistance crisis, has been selected to participate in the Google.org Accelerator: Generative AI – to advance its groundbreaking work in antibiotic research and development. Along with a share of $30 million in funding, Phare Bio will receive 6 months of pro bono technical expertise to support the continued buildout of Phare Bio’s AI-powered, open-access drug discovery platform – a resource designed to galvanize global researchers and reinvigorate antibiotic innovation at a time of mounting public health urgency.
Phare Bio Awarded Up To $27 Million from ARPA-H to Accelerate AI-Powered Drug Discovery and Develop Critically Needed New Classes of Antibiotics
Phare Bio, along with the Collins Lab at the Massachusetts Institute of Technology (MIT) and Harvard's Wyss Institute, today announced that they have been awarded up to $27 million in funding from the Advanced Research Projects Agency for Health (ARPA-H), part of the U.S. Department of Health and Human Services, to enhance their generative artificial intelligence (AI) discovery platform and produce novel classes of antibiotics. With mounting concern around the AMR crisis, there is an urgent need for new antibiotics that have the potential to save millions of lives.
